Appili Therapeutics awarded $2.8M from ACOA, having raised $8.23M in equity and grants from Innovacorp and Bloom Burton & Co. led Canadian and US private investor syndicate Continue Reading
Sierra Oncology, formerly ProNAi Therapeutics, to close public offering with Jefferies acting as the sole book-running managerContinue Reading
Solarvest has secured $1M in financing from Drashta VenturesContinue Reading
Dr. Patrick Soon-Shiong acquired 44,791,488 ProMetic Life Sciences share through exercise of warrants, generating $74.8M in profits. Continue Reading
Sirona Biochem raised $665,360 by way of oversubscribed convertible note private placement. Continue Reading
Ironshore Pharmaceuticals & Development, a wholly owned subsidiary of Highland Therapeutics, raised $200M from Canadian and foreign investors.Continue Reading
VWR (NASDAQ: VWR) has acquired SEASTAR CHEMICALS Inc., a member of the AXYS Group. Madison Dearborn Partners, previously a controlling shareholder, owns 35% of VWR. (photo credit: SEASTAR)Continue Reading
AmorChem has transferred USP15-Deubiquitinylation (Dub) drug discovery platform into a newly formed Corbin Therapeutics together with $1 million seed investment. (photo credit: AmorChem)Continue Reading
Microdermics Inc., a Vancouver based hollow microneedle technology company, has closed a seed round of financing led by e@UBC Seed Fund. (photo credit: Microdermics)
Continue Reading
Terramera, an Ag-Bio Technology leader developing sustainable plant based pest and disease control solutions, has secured additional Series B add-on financing. Continue Reading
Fulcrum Capital Partners Fund V has made an investment in Vitalus Nutrition to support the company growth. The investment is the sixth platform investment made by Fulcrum Capital Partners Fund V, a $344 million 2014 vintage fund.Continue Reading
Exact Imaging has raised CDN $21.5M in Series C from Lumira Capital, Vesalius Biocapital, PMV (Participatiemaatschappij Vlaanderen), iGan Partners and others. The Series C includes conversion of bridge financing closed in April 2016. Continue Reading
Versant Ventures has closed Versant Venture Capital VI, at its hard cap of US $400 million or CDN $538 million, and in a record time. Versant Venture Capital VI family of funds consists of a Delaware main fund and an Ontario parallel fund. Versant Ventures (photo credit: Versant)Continue Reading
